
Recursion Pharmaceuticals is described as a clinical-stage "TechBio company" that leverages artificial intelligence, automation, and extensive biological datasets to streamline drug discovery. By 2025, Recursion established its "Operating System (OS)" as a core tool in AI-native drug development to enhance the speed and success of developing new medicines.